The strength of an
integrated business model
Our integrated business model has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
The assets in our portfolio are differentiated products that either target diseases currently lacking a preventative and effective therapeutic treatment option or that we believe may have meaningful therapeutic advantages relative to other existing vaccine and treatment options.
Our lead program, VLA15, is a Phase 2 vaccine candidate targeting Borrelia, the bacterium that causes Lyme disease, under development in collaboration with Pfizer, and it is the only active vaccine candidate against Lyme disease currently undergoing clinical trials.
To our knowledge, VLA1553 is the only vaccine candidate in Phase 3 targeting the chikungunya virus, which has spread to more than 100 countries and infected more than three million people in the Americas since first appearing there in 2013. We believe that VLA1553 is differentiated from other clinical stage chikungunya vaccine candidates since it is the only candidate that targets long-term protection with a single administration.
VLA2001 is the only inactivated COVID-19 vaccine candidate in clinical development in Europe today.
JUAN CARLOS JARAMILLO Chief Medical Officer
2020 sales were adversely affected by the COVID-19 pandemic impact on the travel industry.
Our manufacturing base provides a long-term and sustainable industrial network to supply clinical trial material and commercial products. We operate three manufacturing sites augmented by contract manufacturing partners.
Valneva has a specialist commercial capability for the distribution of its travelers’ vaccines in key travel vaccine markets.
Franck GrimaudPresident & Chief Business Officer